XML 44 R29.htm IDEA: XBRL DOCUMENT
v3.21.1

Note 3 - Research and Collaboration Agreements, Sublicense Agreement and Investments in Privately Held Companies (Details Textual) € in Millions |  |  |  | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 24, 2020 | May 07, 2019 | Jun. 30, 2017 USD ($) | Jun. 30, 2017 EUR (€) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 01, 2020 | Jul. 08, 2020 shares | Apr. 26, 2019 | Jun. 30, 2017 EUR (€)
Collaborative Arrangement, Duration Of Agreement (Year) |  |  | 2 years | 2 years |  |  |  |  |  |
Collaborative Arrangement, Payment for Research and Development Agreement |  |  | $ 1,100,000 | € 1.0 |  |  |  |  |  |
Research and Development Expense, Related Party |  |  |  |  | $ 0 | $ 868,720 |  |  |  |
Collaborative Arrangement [Member] | Serum [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Number of Antibodies and Vaccines For Development and Commercialization |  | 12 |  |  |  |  |  |  |  |
Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins |  | 12 |  |  |  |  |  |  |  |
Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period (Year) |  | 15 years |  |  |  |  |  |  |  |
Revenue from Collaborative Arrangement, Recognized |  |  |  |  | 244,000 | $ 118,000 |  |  |  |
Novovet [Member] |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  |  |  |  |  |  |  | 20.00% |
Alphazyme [Member] |  |  |  |  |  |  |  |  |  |
Sale of Stock, Percentage of Ownership after Transaction | 2.50% |  |  |  |  |  |  |  |  |
Equity Securities without Readily Determinable Fair Value, Amount |  |  |  |  | $ 284,709 |  |  |  |  |
Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Payment for Additional Development and Commercialization | € |  |  |  |  |  |  |  |  |  | € 1.5
Service Framework Agreement [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Duration Of Agreement (Year) |  |  | 2 years | 2 years |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development |  |  | $ 1,000,000 |  |  |  |  |  |  |
Collaborative Arrangement, Outstanding Commitment |  |  | $ 1,000,000 |  |  |  |  |  |  |
Alphazyme [Member] |  |  |  |  |  |  |  |  |  |
Ownership Percentage |  |  |  |  |  |  | 1.99% |  |  |
ID Biologics Inc [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Number of Shares To Be Received (in shares) | shares |  |  |  |  |  |  |  | 129,611 |  |
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners |  |  |  |  |  |  |  | 0.37% |  |
ID Biologics Inc [Member] | Share-based Payment Arrangement, Tranche One [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Vesting Percentages |  |  |  |  |  |  |  | 50.00% |  |
ID Biologics Inc [Member] | Share-based Payment Arrangement, Tranche Two [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Vesting Percentages |  |  |  |  |  |  |  | 25.00% |  |
ID Biologics Inc [Member] | Share-based Payment Arrangement, Tranche Three [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Vesting Percentages |  |  |  |  |  |  |  | 25.00% |  |
Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Payment for Research and Development Agreement | € |  |  |  | € 1.0 |  |  |  |  |  |
Research Services Agreement [Member] | BDI Holdings [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Duration Of Agreement (Year) |  |  | 2 years | 2 years |  |  |  |  |  |
Collaborative Arrangement, Equity Interest Acquired |  |  | 16.10% | 16.10% |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development |  |  | $ 936,000 |  |  |  |  |  |  |
Collaborative Arrangement, Maximum Obligation For Research and Development | € |  |  |  |  |  |  |  |  |  | 8.0
Research Services Agreement [Member] | BDI Holdings [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development | € |  |  |  |  |  |  |  |  |  | € 1.0
Collaborative Arrangement, Revenue Sharing, Percentage |  |  | 50.00% | 50.00% |  |  |  |  |  |
Research Services Agreement [Member] | BDI Holdings [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Revenue Sharing, Percentage |  |  | 75.00% | 75.00% |  |  |  |  |  |
Research Services Agreement [Member] | VL Pbio Member |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Equity Interest Acquired |  |  | 3.30% | 3.30% |  |  |  |  |  |

X
- Definition Represents duration of agreement for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementDurationOfAgreement
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents equity interest acquired for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementEquityInterestAcquired
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents maximum obligation for research and development for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents minimum obligation for research and development for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of antibodies and vaccines for development and commercialization for collaborate arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementNumberOfAntibodiesAndVaccinesForDevelopmentAndCommercialization
Namespace Prefix: | dyai_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents number of shares to be received for collaborative arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementNumberOfSharesToBeReceived
Namespace Prefix: | dyai_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents number of proteins for option to obtain exclusive commercial sub-lease of collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementOptionToObtainExclusiveCommercialSublicenseForNumberOfProteins
Namespace Prefix: | dyai_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents outstanding commitment for collaborative. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementOutstandingCommitment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents payments for additional development and commercialization for collaborative arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents payment for research and development agreement for collaborate arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents period of milestone payments and royalties for research funding of collaborative arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents percentage of revenue sharing for collaborate arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementRevenueSharingPercentage
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents vesting percentage for collaborative arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementVestingPercentages
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents ownership percentage by noncontrolling owners for noncontrolling interest. + References No definition available. + Details
Name: | dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of ownership. + References No definition available. + Details
Name: | dyai_OwnershipPercentage
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the amount of related-party research and development expense recognized during the period. + References No definition available. + Details
Name: | dyai_ResearchAndDevelopmentExpenseRelatedParty
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents revenue from collaborative arrangement recognized during period. + References No definition available. + Details
Name: | dyai_RevenueFromCollaborativeArrangementRecognized
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_SerumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedContractCostAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedContractCostAxis=dyai_ServiceFrameworkAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_IDBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_BDIHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_VLPbioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |